Efficacy and Side Effects of Narrowband-UVB in Early Stage Cutaneous T-Cell Lymphoma in Jordanian Patients

Table 1

Rates of early stage CTCL response to NB-UVB phototherapy in relation to duration and dose of NB-UVB.

	Complete remission	Partial remission
Patients: % (number)	76.4% (21/27)	23.6% (6/27)
Duration of treatment in weeks: range (mean)	5–14 (12.7)	14
No. of sessions: range (mean)	15–42 (28.9)	42
Cumulative NB-UVB dose in J/cm^2: range (mean)	17.3–48.2 (38.7)	45.7–48.2 (46.6)
Maintenance of remission: % (number)	42.8% (9/21)	N.A.